Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C

Abstract

A novel nucleotide analog polymerase inhibitor developed for HCV treatment may cause a toxic cardiomyopathy. Ongoing surveillance of DAAs for cardiotoxicities may be beneficial, especially among patients at higher risk for cardiovascular disease.